Browse Articles

Discover research articles across all indexed journals

miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape

Nature Communications Fang Chen, Dandan Zhao, Yongfang Xu et al. Feb 01, 2025 DOI: 10.1038/s41467-025-56383-y

Abstract We reported that an acquired miR-142 deficit transforms chronic phase (CP) chronic myeloid leukemia (CML) leukemic stem cells (LSCs) into blast crisis (BC) LSCs. Given the role of miR-142 in the development and activity of the immune system, we postulated that this deficit also promotes LSC immune escape. Herein, we report on IL-6-driven miR-142 deficit occurring in T cells during BC transformation. In CML murine models, miR-142 deficit impairs thymic differentiation of lymphoid-primed multipotent progenitors (LMPP) into T cells and prevents T cells’ metabolic reprogramming, thereby leading to loss of T cells and leukemia immune escape. Correcting miR-142 deficit with a miR-142 mimic compound (M-miR-142), alone or in combination with immune checkpoint antibodies, restores T cell number and immune activity, leading to LSC elimination and prolonged survival of BC CML murine and patient-derived xenograft models. These observations may open new therapeutic opportunities for BC CML and other myeloid malignancies.

Correction: Characterization of a cytochrome P450 that catalyzes the O-demethylation of lignin-derived benzoates

Journal of Biological Chemistry Megan E. Wolf, Daniel J. Hinchen, John E. McGeehan et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108212

Prognosis of signet ring cell (SRC) gastric carcinoma (GC) compared with other histological subtypes.

Journal of Clinical Oncology Rafael Torosian, Sergey Nered, Nikolay Kozlov et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.357

357 Background: Signet ring cell (SRC) gastric cancer (GC) has its unique clinicopathological features with poor tissue differentiation, high invasiveness, diffuse growth pattern and poor prognosis. Survival rates and clinicopathological characteristics of patients with SRC GC regardless of the stage of the disease has not been well studied. Methods: The retrospective analysis was undertaken of 993 patients with diagnosed gastric cancer. These patients received surgical resection in period from January 2013 to December 2018 in N.N. Blokhin National Medical Research Center of Oncology. We compared clinical and pathological features as well as prognostic factors between these groups. Results: For early SRC carcinoma, the median survival rates weren’t reached; 3- and 5-year survival rates were 100% and 89.0 %; for non-SRC carcinoma 91.4 and 85.3 % (HR=0.73; 95 % CI 0.22–2.42, р = 0.6) respectively. For locally advanced/metastatic SRC carcinoma, the median survival rates, 3- and 5-year survival rates were 38 months, 53.0 and 38.4 %; for non-SRC carcinoma 51.1 months, 59.2 and 48.0 % (HR=1.2; 95 % CI 0.91–1.54, р = 0.2). At univariate analysis SRC morphology was found as independent risk factor for overall survival (HR=1.19; CI 95% 0.94 – 1.50; p<0.0001). Multivariate analysis did not reveal SRC morphology to be significant and independent risk factor for overall survival (HR=1.00; CI 95% 0.72 – 1.38; p=0.98). Conclusions: Overall survival rates in patients with early (mucosal and submucosal tumor regardless of lymph nodes status) SRC gastric cancer did not show any significant differences in comparison with other histological types of GC. Thus, the prognosis of early SRC GC is equivalent or better than that of other histological subtypes of GC. Overall survival rates of locally advanced/metastatic SRC gastric cancer are worse than non-SRC cancer, but the differences are not statistically significant.

Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.

Journal of Clinical Oncology Alexander I. Spira, Kyriakos P. Papadopoulos, Dae Won Kim et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.724

724 Background: RMC-9805 is a potent, oral, RAS(ON) G12D-selective, covalent, tri-complex inhibitor targeting the active, GTP-bound state of oncogenic RAS G12D isoforms. Despite low response rates to current standard of care (SOC), no RAS-targeted therapy is approved for G12D PDAC. Methods: In this Phase 1 study (NCT06040541), patients with previously treated, advanced KRAS G12D solid tumors received escalating RMC-9805 doses (150-1200 mg once daily [QD] or 300-600 mg twice daily [BID]). Treatment cycles were every 3 wks. Antitumor activity was assessed every 6 wks the first 24 wks then every 9 wks. Additional patients were enrolled at RMC-9805 doses that cleared the dose-limiting toxicity (DLT) evaluation to further characterize pharmacokinetics, safety, antitumor activity, and biomarkers. Plasma for ctDNA analysis was collected at baseline (BL; cycle 1, day 1 [C1D1] or screening), and on treatment (OT; C2D1 or C3D1). Results: As of Sept 2, 2024, 179 patients with KRAS G12D solid tumors (most having PDAC; n=104 [58%]) received 5 escalating dose levels of RMC-9805 (150-1200 mg daily). No DLTs or Grade 4 or 5 treatment-related adverse events (TRAEs) were reported, and the maximum tolerated dose (MTD) was not reached. Among patients who received a candidate recommended phase 2 dose (RP2D) of 1200 mg daily (1200 mg QD [n=60] or 600 mg BID [n=39]), the most common (≥10% of patients) TRAEs were nausea (27%), diarrhea (20%), vomiting (15%), and rash (10%), all of which were Grade 1 or 2 severity. One Grade 3 TRAE (ALT elevation) was observed in a patient with PDAC and a history of ALT elevation, biliary stenting, and liver metastasis. No patients treated with 1200 mg daily discontinued treatment due to TRAEs and 4% of patients had dose reductions due to TRAEs. In patients with PDAC receiving RMC-9805 daily at 1200 mg QD (n=20) or 600 mg BID (n=20) who enrolled at least 14 wks prior to data cutoff, the objective response rate (confirmed response or pending confirmation) was 30%, and the disease control rate was 80%. Of 28 patients who had KRAS G12D mutations detected in ctDNA at BL and were evaluable for OT assessment, 86% had an OT decrease >50% from BL of detectable KRAS G12D mutations, and 39% had a 100% OT clearance. Updated data will be presented. Conclusions: Oral RMC-9805 showed encouraging initial antitumor activity with early and deep reductions in KRAS G12D ctDNA in patients with KRAS G12D PDAC. Tolerability was favorable relative to SOC chemotherapy for PDAC and manageable. This overall safety profile and antitumor activity support continued evaluation as monotherapy in patients with KRAS G12D PDAC, and in combination with chemotherapy and targeted therapies, including the RAS(ON) multi-selective inhibitor RMC-6236. Clinical trial information: NCT06040541 .

Prognosis of patients with liver single-organ metastases: Updated survival results of BBCAPX-II.

Journal of Clinical Oncology Ying Yuan, Ning Zhu, Xuefeng Fang et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.157

157 Background: Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) especially with liver metastases have a low response rate to immunotherapy. Sintilimab plus bevacizumab and CapeOX (BBCAPX) has proved its efficacy and safety in above unresectable mCRC patients (1). Here, we report subgroup analysis of updated survival results of this single arm, open-label, phase 2 trial. Methods: Eligible patients were histologically confirmed unresectable metastatic colorectal adenocarcinoma by multidisciplinary team, and had RAS gene mutation and confirmed MSS status. All patients received treatment with sintilimab plus bevacizumab, oxaliplatin and capecitabine of each 21-day cycle. ORR, DCR, PFS, OS, and subgroup analyses based on metastasis site were performed. Results: From April 2021 to December 2021, 25 patients were enrolled. The ORR was 84% and the DCR was 100%. Six (24%) patients including 5 patients with liver single organ metastases underwent surgical treatment and unexpectedly achieved no evidence of disease status. At the data cut-off day (September 13, 2024), patients with liver single organ metastases presented better prognosis. Median PFS was 25.3 months (95% CI, 4.8-NA) in the patients with liver single organ metastases and 11.5 months (95% CI, 4.83-24.3) in the patients with other metastasis. Median OS was not reached in the patients with liver single organ metastases and 35.5 months (95% CI, 9.36-NA) in the patients with other metastasis. The OS rate at 24 months was 72% (95% CI, 56.4-91.9) in FAS. Median OS was not reached in FAS and 35.5 months (95% CI, 11.4-NA) in PPS. 32% patients had at least one grade 3 or 4 TRAEs. No grade 5 adverse events occurred during the study. Conclusions: This study provides a highly promising regimen for patients with RAS-mutant, MSS, unresectable mCRC, especially those with liver single organ metastases. Furthermore, we are launching a phase III, randomized, open-label, multicentric clinical trial (NCT05171660) to further analyze the effects, safety, and prognostic biomarkers of this regimen. 1. Xuefeng Fang et al. ASCO 2022. Clinical trial information: NCT04194359 . PFS and OS results of BBCAPX-II study. Median PFS 6m PFS rate (%) 12m PFS rate (%) Median OS 12m OS rate (%) 24m OS rate (%) Full analysis set (FAS), n = 25 17.9 (95% CI, 8.84-27) 84 (70.8-99.7) 56 (39.6-79.3) NA 76 (61-94.7) 72 (56.4-91.9) Per-protocol set (PPS), n = 19 9.79 (95% CI, 6.44-27.9) 78.9 (62.6-99.6) 42.1 (24.9-71.3) 35.5 (95% CI, 11.4-NA) 68.4 (50.4-92.9) 63.2 (44.8-89) Classified by metastatic organs (FAS, n = 25) Liver single organ metastases, n = 10 25.3 (95% CI, 4.8-NA) 90 (73.2-100) 70 (46.7-100) NA (11.4-NA) 90 (73.2-100) 80 (58.7-100) Other metastases, n = 15 11.5 (95% CI, 4.83-24.3) 80 (62.1-100) 46.7 (27.2-80.2) 35.5 (9.36-NA) 66.7 (46.6-95.3) 66.7 (46.6-95.3)

Maternal obesity alters histone modifications mediated by the interaction between EZH2 and AMPK, impairing neural differentiation in the developing embryonic brain cortex

Journal of Biological Chemistry Thilina T. Alawathugoda, Muhammad Abid Sheikh, Anil Kumar Challagandla et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108173

Comparative analysis of demographics and outcomes in hospitalized patients with young- versus average-onset colorectal cancer in New York state (2017-2022).

Journal of Clinical Oncology Mrinalini Ramesh, Yasmin Fakhari-Tehrani, Vaishali Deenadayalan et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.27

27 Background: Recent studies have shown an increasing incidence of colorectal cancer (CRC) among young patients. This study investigates clinical outcomes and healthcare utilization among young (<50) versus average onset (≥50) CRC patients admitted to hospitals in New York State (NYS). Methods: We performed a retrospective analysis using the Statewide Planning and Research Cooperative System (SPARCS) database from 2017 to 2022. Patients were divided into two groups: young-onset colorectal cancer patients (YOCRC, <50 years) and average onset colorectal cancer patients (AOCRC, ≥50 years). The study population was further stratified by demographic and clinical characteristics. All associations were compared using the Kruskal-Wallis test, along with multivariate linear and logistic regression in RStudio version 4.4.1, at a significance level of ≤0.05. Clinical characteristics, including severity of illness and risk of mortality, were defined using the All Patient Refined (APR) grading system. Results: A total of 9,904 patients were identified (948 YOCRC and 8,956 AOCRC) with a primary admitting diagnosis of CRC from 2017 to 2022. In comparing the two age groups, AOCRC patients had a higher proportion of White, and female patients, whereas the YOCRC group included a higher proportion of Black and male patients (p<0.001). The median length of stay was greater for AOCRC patients (5 days) compared to YOCRC patients (4 days), p<0.001. Both age groups showed an upward trend in total cost of stay in the recent years. AOCRC patients were more likely to have increased severity of illness graded as major-extreme (60% vs 48%), while a higher proportion of YOCRC patients were classified as minor-moderate disease (51% vs 40%), p<0.001. Similarly, AOCRC patients experienced a higher risk of mortality compared to YOCRC patients (p<0.001). Regarding procedures, AOCRC patients needed more transfusions (13%) than YOCRC patients (9.3%), p<0.001. YOCRC patients were also more likely to be discharged home (71% vs 46%), while AOCRC patients often required home health services or skilled nursing (p<0.001). Notably, while the risk of mortality was higher for AOCRC patients, it has been decreasing overall from 2017 to 2022 [OR 0.92 (95% CI: 0.84-0.99), p=0.039]. Conclusions: AOCRC patients experienced greater severity of disease, higher mortality risk, and required more assistive care at discharge compared to YOCRC patients. The total cost of hospital stays has been rising for both groups. Policies focused on earlier outpatient interventions may help reduce the burden of inpatient care and rising costs.

The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial.

Journal of Clinical Oncology Aldina Pivodic, Göran Carlsson, Åke Hjalmarson Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.205

205 Background: To study the compliance in handling the investigational medicinal product (IMP) and its impact on outcomes in patients with metastatic colorectal cancer participating in the AGENT trial (NCT03750786). Methods: In a randomized, multicenter, multinational, phase III study, patients were randomized to receive either arfolitixorin (n=245) or leucovorin (n=245) with 5-fluorouracil (5-FU), oxaliplatin and bevacizumab as a first-line treatment. Logistic regression was applied for overall response rate (ORR) and Cox regression for all-cause death, and all-cause death or progression, adjusted for randomization strata. Results: Missing or incorrect IMP handling was reported for 28 (11%) patients in the arfolitixorin and 23 (9%) in the leucovorin arm, <80% compliance for duration of bolus 5-FU 2-4min for 101 (42%) and 97 (41%), respectively. Considering the time between the bolus 5-FU and arfolitixorin, non-compliance, defined by <80% doses given within 25-35min PP window, was reported for 92 (38%) in arfolitixorin patients. Adherence to the timing between the first and second arfolitixorin dose (30-60min) was high. In total, 91 (37%) patients in the arfolitixorin and 134 (55%) in the leucovorin arm fulfilled PP definitions (cPP population). The bolus 5-FU dose was equally likely to be reduced in both the arfolitixorin and leucovorin arms across regions (ranging from 22% to 39%), except for Japan where 55% of patients in the arfolitixorin arm had their bolus 5-FU dose reduced, compared to 28% in the leucovorin arm. In the cPP population, the ORR was achieved by 54 (59%) in the arfolitixorin and 69 (51%) in the leucovorin arm, adjusted odds ratio (aOR) 1.40 (95% CI 0.81-2.45), p=0.23. Excluding Japan, the ORR was 41 (62%) in the arfolitixorin and 49 (46%) in the leucovorin arm, aOR 2.11 (95% CI 1.09-4.06), p=0.026. Corresponding aOR for Europe was 1.50 (95% CI 0.71-3.15), p=0.29, and for North America aOR 7.95 (95% CI 1.45-43.62), p=0.017. In Japan, the ORR had better outcome in the leucovorin arm (71.4%) compared to the arfolitixorin arm (52.0%), aOR 0.42 (95% CI 0.13-1.31), p=0.14. However, the relationship was numerically opposite for patients without bolus 5-FU dose reduced. All-cause death during the complete follow-up was reported for 37 (41%) in the arfolitixorin and 61 (46%) in the leucovorin arm. Conclusions: In the AGENT trial, 46% of the included patients met per protocol compliance for treatment handling. In this cPP population, there was a non-significant, but clinically relevant, increase in the overall response rate in the arfolitixorin compared to the leucovorin arm. Notably, in all regions excluding Japan, the overall response rate was higher for arfolitixorin, with statistical significance. Adherence to the treatment protocol is crucial for the outcomes of patients with metastatic colorectal cancer. Clinical trial information: NCT03750786 .

Refining colorectal cancer screening strategies using polygenic risk scores and classical risk factors: A proof-of-concept study in the UK Biobank cohort.

Journal of Clinical Oncology Elle Kim, Nilanjan Chatterjee Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.104

104 Background: While the rising incidence of CRC in younger populations has led to a push for lowering the screening age to 40, current clinical guidelines lack sufficient consideration of individual risk variations, raising concerns about the potential harms of over-diagnosis and false positives. Our proof-of-concept study evaluates the utility of risk stratification for multi-target stool DNA (mt-sDNA) testing by integrating polygenic risk scores and traditional clinical risk factors, addressing gaps in current clinical CRC screening guidelines. Methods: Our study utilized the UK Biobank prospective cohort, consisting of 311,544 unrelated individuals of White British ancestry, aged 40-69, excluding those with any prior malignant cancer diagnosis. We developed a sex-specific Cox proportional hazards model to estimate the risk of developing CRC, with the primary outcome being the first incidence of CRC. Three models were assessed: a polygenic risk score (PRS)-only model, a classical risk factors (RF)-only model, and a combined (PRS + RF) model. The traditional risk factors considered were BMI, smoking status, pack years of smoking, and family history of bowel cancer in first-degree non-adoptive relatives. Model performance was evaluated using the area under the curve (AUC), hazard ratios (HR), and the positive and negative predictive values of mt-sDNA across various risk profiles. Results: The combined model for early CRC screening using mt-sDNA demonstrated superior risk stratification (Table) and improved PPV compared to the risk factors-only model, with enhanced performance even among younger individuals at lower baseline risk. If risk stratification was not used, the average PPV for the test in the general population (ages 40-80) would be 2.13% for males and 1.44% for females. In contrast, individuals in the top 1% of risk would have significantly higher PPVs: 5.62% for males and 3.51% for females. If we limit testing to only the high-risk group, per 100,000 individuals, approximately 3,490 additional cases for males and 2,070 additional cases for females would be detected compared to the average-risk population without stratification. Conclusions: The findings suggest that risk stratification may enhance the effectiveness of screening by identifying high-risk individuals who would derive the greatest benefit. In contrast, broad application of the test across the general population may not achieve an optimal risk-benefit ratio, given the relatively low PPV in average-risk individuals. Model performance of the PRS-only, RF-only, and PRS + RF (Combined) models for females and males, respectively. Hazard Ratio (95% CI) C-index (SE) 5-Year AUC Female PRS-Only 1.50 (1.37 - 1.64) 0.62 (0.01) 0.61 RF + PRS 1.49 (1.36 - 1.63) 0.62 (0.01) 0.61 RF Only 1.09 (0.99 - 1.20) 0.53 (0.02) 0.51 Male PRS-Only 1.49 (1.38 - 1.61) 0.63 (0.01) 0.69 RF + PRS 1.49 (1.38 - 1.61) 0.64 (0.01) 0.71 RF Only 1.23 (1.15 - 1.31) 0.57 (0.01) 0.57

EORTC1527/JCOG1609INT/ESSO02: Diffusion-weighted magnetic resonance imaging (DW-MRI) assessment of initially unresectable liver metastasis to improve surgical planning (DREAM)—Primary analysis.

Journal of Clinical Oncology Kozo Kataoka, Murielle E. Mauer, Manabu Shiozawa et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.257

257 Background: Disappearing liver metastases (DLMs) diagnosed on post-chemotherapy (Cx) computed tomography (CT) is a favorable prognostic factor in patients (pts) with colorectal liver metastases (CRLM). However, the optimal treatment of DLMs - whether they should be resected or left behind - is controversial. This is a prospective, multi-centred, international study examining the added value of MRI (DWI, T1/T2 and contrast-enhanced) to that of CT alone in accurate assessment of the viability of DLMs. Methods: Pts with initially unresectable CRLM downstaged to a planned liver resection after Cx were enrolled, based on the obligatory decision of a multidisciplinary team. Pts were imaged by both CT and MRI at baseline and presurgical timepoints. DLMs were defined as disappeared lesions diagnosed by CT alone, while confirmed DLMs (cDLMs) were defined as lesions that disappeared on both CT and MRI. cDLMs were either resected or followed-up for 2 years if not resected. All imaging scans were collected centrally for quality assurance. The primary endpoint was the negative predictive value (NPV) of MRI and CT in confirming the status of cDLMs using either pathological complete response or the absence of a local recurrence at the site of cDLMs during the 2 year follow up. The study was aimed at excluding a NPV ≤0.85 with a 1-sided alfa of 5% and power of 90% under the alternative that the NPV ≥0.95. The planned sample size was 92 evaluable (resected or left behind) cDLMs, assuming a within-patient correlation between cDLMs of 0.2 and an average number of 2 cDLMs per pt. Results: 233 pts were registered at 22 participating centres, and 112 were enrolled for analysis. A median of 8 cycles of Cx was delivered, and pts had a median of 7 CRLMs at baseline. A total of 203 cDLMs were identified while the number of DLMs diagnosed by CT was 296. Of these, 152 cDLMs and 227 DLMs, respectively, were evaluable according to the imaging protocol. Intraoperative ultrasound was performed for 195 cDLMs and, of these, 59 (30.2%) were still detected. The rate of R0/R1 resection was 95.5%. The NPV of evaluable cDLMs either resected or left behind was 62.5 % (95/152, 95% CI:50.8-74.2), which was lower than the prespecified threshold. The NPV of DLMs was 52.9% (119/227, 95% CI:42.7, 63.0). The NPV of resected cDLMs, and those left behind were 56.8% (50/88, 95% CI: 44.2, 69.5) and 70.3% (45/64, 95% CI: 48.6 -92.0), respectively. For DLMs, the NPV of resected DLMs and those left behind were 45.6% (72/158, 95% CI: 35.4-55.7) and 69.6% (48/69, 95% CI: 47.7-91.5), respectively. Conclusions: For pts with initially unresectable CRLM, cDLMs diagnosed by both CT and MRI do not correspond to tumor viability, even after highly effective chemotherapy. Ongoing survival analysis (to be presented at the annual meeting) may impact the treatment strategy of pts with DLMs. Clinical trial information: NCT02781935 .

Pancreatic expression of CPT1A is essential for whole body glucose homeostasis by supporting glucose-stimulated insulin secretion

Journal of Biological Chemistry Maggie P. Ducote, Caroline R. Cothern, Heidi M. Batdorf et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108187

Analysis of tumor microenvironmental features of primary and synchronous liver metastases from patients with colorectal cancer using a deep learning algorithm.

Journal of Clinical Oncology Oluwadunni Eunice Emiloju, Bahar Saberzadeh Ardestani, Rory L Smoot et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.251

251 Background: The development of colorectal liver metastases (CRLM) is associated with poor prognosis, and recent data suggest that metastasis to the liver is associated with resistance to immunotherapy. We characterized the microenvironment of primary colorectal carcinomas (CRCs) relative to their synchronous CRLM using a validated segmentation algorithm that quantifies 15 distinct morphologic tumor features. Methods: Adult CRC patients with synchronous CRLM (N=57) at Mayo Clinic were identified from the electronic health record using Epic Slicer Dicer and from an internal database. Tumor H&E sections were digitized and reviewed for quality control (RKP). QuantCRC (Aiforia, Inc) was applied to digitized images to extract 15 GI pathologist pre-defined morphological features. Tumor features were compared between primaries and CRLM using the Kruskal–Wallis test. The project was approved by the Mayo Clinic Institutional Review Board. Results: The study included 57 patients (median age 59 years [IQR 50, 73], 51% female) with CRC primaries and synchronous CRLM. Among primaries, 20 (35%) were right-sided and 37 (65%) were left-sided. QuantCRC identified 6 of 15 morphological features that differed significantly between primaries and their CRLM, including reduced stroma, more high-grade and necrosis, and a higher tumor: stromal ratio (TSR) in CRLM (Table). The increase in TIL density in CRLM vs the primary tumor was of borderline significance (p =0.053). Among patients with left-sided primary tumors, their CRLM had significantly higher TSR, percent high-grade, percent necrosis, and TIL density compared to the primary (all p values ≤ 0.02). Among right sided primaries, CRLM had a significantly reduced percent mature stroma (p=0.034) whereas percent necrosis was increased (p =0.01). Conclusions: Using deep learning, we identified tumor morphological features that differed significantly between primary CRC and their synchronous CRLM. This included higher TSR in CRLMs compared to primaries that is associated with epithelial-mesenchymal transition and has been shown to contribute to treatment resistance. Analysis of tumor morphological features with patient prognosis is ongoing. Deep learning-derived morphological features of primary CRC and CRLM. Morphological feature (Median) Primary tumor Liver metastasis P-value Tumor-Stroma Ratio 0.78 1.50 0.008 % High-grade 23.08 31.72 0.005 TIL Count 44.36 60.20 0.053 % Necrosis 6.35 19.32 <0.001 %Signet Ring Cells 0.25 0.13 0.088 TB/PDC 0.89 1.13 0.484 % Stroma 54.89 40.98 <0.001 % Immature Stroma 46.76 34.13 <0.001 % Mature Stroma 6.27 5.08 0.030

Telotristat ethyl to promote weight stability in patients with advanced pancreatic cancer.

Journal of Clinical Oncology Olumide B. Gbolahan, Elham Babadi, Tarrant McPherson et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.747

747 Background: Cachexia a key feature of pancreatic ductal adenocarcinoma (PDAC), affects up to 80% of patients (pts), and is associated with worse outcomes. Serotonin, due to its tumorigenic potential and effect on gut function may contribute to weight loss in PDAC. Telotristat ethyl (TE) inhibits serotonin production and improves gut motility dysfunction. We developed a phase II trial to evaluate the impact of TE on the weight of patients with metastatic PDAC (mPDAC) receiving first-line chemotherapy. Methods: Treatment-naïve pts with mPDAC who had lost at least 10% of baseline weight (Group 1) received gemcitabine and nab-paclitaxel (GnP) in combination with TE (250mg administered orally three times a day). Pts with < 10% weight-loss were recruited in Group 2 and received chemotherapy without TE. Serum serotonin was collected monthly during the study. The primary endpoint was weight stability, evaluated as % weight change at 3 months compared to baseline, with a goal of < 5% decrease. A key secondary endpoint was change in serotonin levels at 3 months compared to baseline. The groups were analyzed independently. Results: We enrolled 22 pts, 14 in group 1 (planned 40) and 8 in group 2 (planned 40). The median age was 70 years (IQR 62-75), majority were male (n = 15; 68%) and 11 (50%) were Black. Mean weight at treatment start was 77.9 kg (SD 19.16) group 1, and 90.6kg (SD 24.71) group 2. Mean serotonin level at baseline was 165.07 ng/ml (SD 60.49) group 1, and 296.9 ng/ml (SD 166.65) group 2. Mean % weight change over 3 months in group 1 was -2% (90% CI -5.2 to 1.3, P < -5% = 0.0595). Mean change in group 2 was -5.6% (90% CI -9.4 to -1.7%, P < 5% = 0.53). At 3 months, the median change in serotonin level in group 1 was -37.8% (IQR -59.1 to -13, P = 0.064) and -42.6% (IQR-57.8 to -29.9, P = 0.016) for group 2. Adverse events (AE) were consistent with known AE for GnP and TE. The median overall survival was 10.7 months (95% CI 5.4-16.9) group 1 and 12.2 (95% 6.1 to 21.4) group 2, HR 1.41 (95% CI 0.57 to 3.52 P = 0.46). Conclusions: Among pts with mPDAC and cachexia, the addition of TE to chemotherapy led to weight stabilization. These pts experienced 2% weight loss on average during the study (the upper limit of the CI just crossed -5% at -5.2%). The average weight loss was 5.6% in those who did not receive TE suggesting a signal of activity. A larger study is warranted to evaluate the role of TE in the management of cachexia in mPDAC. Funded by Lexicon Pharmaceuticals (NCT03910387). Clinical trial information: NCT03910387 .

The role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011-2023.

Journal of Clinical Oncology Keitaro Shimozaki, Akira Ooki, Koichiro Yoshino et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.404

404 Background: Although the appearance of immunotherapy has apparently brought benefits for all patients (pts) with advanced gastric cancer (AGC), the magnitude of the benefit in real-world pts with HER2-negative AGC has not been fully investigated. Methods: We conducted a retrospective study on pts with HER2-negative AGC who received first-line platinum-based chemotherapy between 2011 and 2023. We evaluated the clinical outcomes across different periods of immunotherapy approval in Japan: Group A (pre-immunotherapy approval): 2011-2017, Group B (approved for third-line treatment or later): 2018-2021, and Group C (approved for first-line treatment): 2022-2023. Results: A total of 949 pts were enrolled (A: n = 477; B: n = 344; C: n = 128). Patient's characteristics were comparable except for the proportion of those with age ≥75 years (P = 0.002), prior gastrectomy (P = 0.03), and liver metastases (P < 0.001). The median overall survival (OS) was 16.2, 15.2, and 21.3 months in group A, B, and C, respectively, with no significant difference between groups (log-rank P = 0.50). Pts who had received first-line immunotherapy plus chemotherapy (n = 173) showed significantly improved OS compared with pts without having received any immunotherapy-containing treatment at 2011-2017 (n = 382) (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.61-0.99; P = 0.04). In the multivariate analysis, the use of immunotherapy at first-line treatment was not significantly associated with worse OS, whereas the use of immunotherapy at any lines was prognostic (HR, 0.54; 95% CI, 0.41-0.71; P < 0.0001). The proportion of pts who had received any second-line treatment was comparable among groups: 76%, 80%, and 71%, respectively. Conclusions: Our study suggests that the immunotherapy might partially have an impact on the survival improvement of real-world pts with HER2-negative AGC, which calls for the need for appropriate treatment strategies, including other agents.

Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer.

Journal of Clinical Oncology Chenchen Wang, Wenhua Li, Xiaodong Zhu et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.167

167 Background: The irinotecan based chemotherapy in combination with bevacizumab had become the standard second-line treatment for metastatic colorectal cancer (mCRC), but the efficacy was limited. Anlotinib, an oral anti-angiogenic tyrosine kinase inhibitor, had initially shown promising clinical effects when combined with chemotherapy in the first-line treatment of mCRC. Whether anlotinib could bring clinical benefit in the second line treatment warrants further exploration. The PD-1 antibody might have partial effects when combined with anti-angiogenic agents with or without chemotherapy in first- and third-line treatment for proficient mismatch repair (pMMR)/microsatellite stable (MSS) mCRC. Our study was to explore the rationality of anlotinib plus chemotherapy or further combined with a novel anti-PD-1 IgG1 antibody—penpulimab in the second line treatment of mCRC. Methods: This study was an open label, non-randomized, multi-cohorts, phase II prospective clinical trial that included pts with pMMR/MSS mCRC who were eligible for the second-line systemic treatment. Two cohorts were established as follows: Cohort A consisted of anlotinib(10mg daily, d1-10, q2w) + irinotecan (180mg/m d6, q2w) (n = 23); Cohort B consisted of anlotinib (8mg daily, d1-10, q2w)+irinotecan (180mg/m d6, q2w) + penpulimab (200mg, d6, q2w) (n = 23). The primary endpoint was ORR. Secondary endpoints included progress free survival (PFS), overall survival (OS), duration of response (DoR), disease control rate (DCR) and safety. The ORR was reported at 2024 ASCO, and PFS and OS have been updated in this report. Results: At the cutoff date on August 2024, a total of 23 Pts were enrolled in A cohort, and 23 pts were enrolled B cohort but 21 pts received at least one dose of treatment. The median PFS was 7.87 months (95% CI 5.52-10.22) in A cohort, compared to 7.4 months (95% CI 3.17-11.63) in B cohort, p=0.141. The 6-month, 12-month and 18-month PFS rates in A cohort and B cohort were 69.3% vs 80.7%, 27.5% vs 40.3% and 5.5% vs 22.4%, respectively. The median OS of A cohort was 21.73 months (95% CI 9.43-34.03), compared to 19.17 months (95% CI 11.44-26.90 months) in B cohort, p=0.987. The 12-month and 24-month OS rates in A cohort and B cohort were 64.7% vs 73.1% and 20.2% vs 54.8%, respectively. Safety profile indicated that 65.2% (15/23) and 66.7% (14/21) experienced grade≥3 adverse events in A cohort and B cohort, respectively. Common grade ≥ 3 adverse reactions (≥ 20%) mainly include hypertension (4.35% vs 14.29%), diarrhea (13.04% vs 9.52%), neutrophilopenia (39.13% vs 33.33%), and leukopenia (26.09% vs 9.52%). Conclusions: There was no statistically significant difference in overall efficacy between the two cohorts, but the long-term PFS and OS rates were higher in group B cohort, indicating that immunotherapy may bring long-term survival benefits to certain patients. Clinical trial information: NCT05229003 .

Missense mutations of the ephrin receptor EPHA1 associated with Alzheimer’s disease disrupt receptor signaling functions

Journal of Biological Chemistry Mike Matsumoto, Maricel Gomez-Soler, Sara Lombardi et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108099

<i>TP53</i> Y220C mutations in pancreatic ductal adenocarcinoma (PDAC): A genomic landscape study.

Journal of Clinical Oncology Hannah Ruth Robinson, Dean Pavlick, Nicole Baranda Balmaceda et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.761

761 Background: A novel targeted therapy designed to restore wild-type function to the p53 Y220C mutant protein has demonstrated promising activity in an early-phase trial (NCT04585750). While the TP53 Y220C mutation is found in &lt; 1% of all solid malignancies, its prevalence is enriched in certain cancers including PDAC. Here we report results of comprehensive genomic profiling (CGP) in a cohort of patients with advanced PDAC, with a focus on TP53 Y220C mutations. Methods: A total of 27,377 cases of clinically advanced PDAC underwent hybrid capture-based CGP to assess all classes of genomic alterations (GAs). Cases were sequenced to a mean coverage depth of 650X. Microsatellite instability (MSI) status and tumor mutation burden (TMB) were determined using sequencing data; PD-L1 expression was measured by immunohistochemistry (Dako 22C3, tumor proportion score [TPS]). Results: TP53 Y220C alterations were identified in 488 (1.8%) PDAC patients (Y220C+). In comparison to PDAC patients lacking the TP53 Y220C alteration (Y220C-), Y220C+ patients were of similar age, but were more likely to be female (52.9% vs 46.8%; p = 0.0008) and harbor KRAS mutations (96.7% vs 92.7%; p = 0.007). Meanwhile, alterations in ATM were more frequent in the Y220C- group (4.0% vs 1.4%; p = 0.0008). Frequencies of other GAs were similar between Y220C+ and Y220C- groups, including alterations in the homologous recombination defect-associated genes BRCA1/2 and RAD21 , as well as ERBB2 , BRAF , MTAP and PIK3CA . MSI-high status and elevated TMB (≥ 10 mutations/Mb) were extremely uncommon in both groups. PD-L1 expression was similar in the Y220C+ and Y220C- groups, with positive PD-L1 expression (TPS ≥ 1) observed in 31.5% and 34.9% of patients, respectively. Conclusions: The potentially targetable TP53 Y220C mutation was identified in close to 2% of clinically advanced PDAC cases. Those with TP53 Y220C mutations were more likely to be female and harbor KRAS mutations, and less likely to harbor ATM mutations. However, TP53 Y220C mutations were not associated with other distinct genomic characteristics. These findings are consistent with previous reports of interactions between TP53 and KRAS alterations in PDAC. Given the emergence of drugs aimed at restoring p53 function in cases with the Y220C mutation, further study of this alteration in PDAC is warranted. Age, number of genomic alterations (GA) per tumor, and alteration frequency of select commonly altered genes based on TP53 Y220C status. TP53 Y220C+ (n = 488) TP53 Y220C- (n = 26,889) P Value Median Age, years (range) 66 (36-89+) 66 (21-89+) NS GA/tumor 5.2 5.0 NS KRAS 96.7% 92.7% 0.007 CDKN2A 60.1% 56.6% NS CDKN2B 28.6% 29.5% NS MTAP 24.4% 23.8% NS ARID1A 7.8% 8.7% NS ATM 1.4% 4.0% 0.0008 BRCA2 2.3% 3.1% NS NS = non-significant.

Patient-centered adverse event reporting in clinical trials: A novel approach using ECOG-ACRIN E2211.

Journal of Clinical Oncology Wan Ying Tan, Laura D. Cramer, Noah Graham et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.658

658 Background: The Common Terminology Criteria for Adverse Events (CTCAE) classifies adverse events (AEs) in clinical trials but traditionally limits the analysis to a single occurrence per patient and grade 3-4 AEs, overlooking frequent and lower grade AEs. We propose a new approach of AE reporting that captures both the safety profile and patient experience. Methods: We analyzed related AEs collected in the ECOG-ACRIN E2211 [Phase II capecitabine + temozolomide (Arm A) vs. temozolomide (Arm B) in advanced pancreatic neuroendocrine neoplasms] by CTCAE v4.0 and limited to hematologic and gastrointestinal (GI) categories for this exploratory analysis. We calculated AE burden, defined as the average occurrence of AE per patient experiencing the AE, measured by total occurrence of AEs, and divided by number of patients who developed the AE. We then compared burden of grade 3-4 AEs vs. grades 1-4 AEs. Sex differences were evaluated using t-tests. Results: For hematologic AEs, 72 patients reported 426 occurrences across grades 1-4 and 24 patients reported 39 occurrences for grades 3-4, resulting in AE burdens of 5.9 (grades 1-4) versus 1.6 (grades 3-4). For GI AEs, 108 patients reported 997 grade 1-4 events, and 13 patients reported 22 grade 3-4 events, resulting in AE burdens of 9.23 versus 1.69, respectively. Sex differences in AE burden are tabulated below (Table). For example, in Arm B, anemia burden was 4.8 (males) vs 2.7 (females) [p=0.068] for grades 1-4 and 0 (males) vs 1 (females) for grades 3 and 4. Conclusions: This AE reporting approach, accounting for the burden across grade 1-4, offers a different and more patient-centered assessment of AEs in clinical trials and may help better identify sex-based differences. Burden of AEs by treatment arm and sex distribution. Burden of Related AEs Categories of AEs Arm A (N=65) Arm B (N=68) Grade 1-Grade 4 Grade 3-Grade 4 Grade 1-Grade 4 Grade 3-Grade 4 Male Female p-value Male Female p-value Male Female p-value Male Female p-value Hematologic Anemia 2.9 3 0.937 0 0 4.8 2.7 0.068 0 1* Neutropenia 1.7 2.2 0.686 1 1* 1.2 2.3 0.064 1 1.1 0.356 Thrombocytopenia 4.3 2.6 0.241 1* 1.2 3.6 3.3 0.781 1 1 ** Gastrointestinal Abdominal pain 2.5 2.2 0.835 0 0 3.1 3 0.955 0 1* Constipation 4.1 3.2 0.515 1* 0 4.9 3.3 0.169 0 0 Diarrhea 1.8 3.6 0.158 0 0 2.6 2.5 0.940 1.25 1 0.390 Nausea 4.2 4.9 0.619 0 0 4.4 4.2 0.893 1 1** ** Vomiting 2.2 1.9 0.703 0 0 1.8 2.8 0.241 1 1 ** *Only 1 patient in each group **No variance within each group.

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma.

Journal of Clinical Oncology Do-Youn Oh, Jianming Xu, Josep Tabernero et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps511

TPS511 Background: Treatment options for patients with gastroesophageal adenocarcinoma (GEA) are limited and prognosis is poor. KEYMAKER-U06 is a multicenter, open-label, phase 1/2, umbrella platform study designed to evaluate investigational agents with or without pembrolizumab and/or chemotherapy for GEA. Substudy 06C (NCT06469944) will be conducted to evaluate sacituzumab tirumotecan(TROP2 antibody-drug conjugate; formerly MK-2870/SKB264) plus pembrolizumab plus investigator’s choice of chemotherapy as first-line therapy for patients with advanced or metastatic GEA. Substudy 06D (NCT06445972) will be conducted to evaluate sacituzumab tirumotecan plus paclitaxel as second-line therapy for patients with advanced or metastatic GEA. Methods: In both substudies, patients aged ≥18 years with confirmed advanced or metastatic HER2-negative GEA (gastric, gastroesophageal junction, or esophageal adenocarcinoma), measurable disease per RECIST v1.1 by investigator review and verified by blinded independent central review (BICR), and an Eastern Cooperative Oncology Group performance status score of 0 or 1 are eligible; patients in substudy 06C should be treatment naive and patients in substudy 06D should have disease progression on or after 1 prior therapy. Both substudies will have a safety lead-in phase of ≤10 patients to determine the recommended phase 2 dose of sacituzumab tirumotecan when used in combination with pembrolizumab plus chemotherapy (substudy 06C) or paclitaxel (substudy 06D). In the safety lead-in phase, patients will receive sacituzumab tirumotecan 3 mg/kg or 4 mg/kg IV per a Bayesian optimal interval design. In the efficacy phase of substudy 06C, ≅120 patients (including 10 patients in safety lead-in) will be allocated or randomly assigned to receive pembrolizumab 400 mg IV every 6 weeks plus investigator’s choice of chemotherapy (arm 1) or sacituzumab tirumotecan IV on days 1, 15, and 29 of each 6-week cycle plus pembrolizumab plus investigator’s choice of chemotherapy (arm 2). In the efficacy phase of substudy 06D, ≅80 patients (including 10 patients in safety lead-in) will be allocated or randomly assigned to receive ramucirumab 8 mg/kg IV on days 1 and 15 of each 4-week cycle plus paclitaxel 80 mg/m 2 IV on days 1, 8, and 15 of each 4-week cycle (arm 1) or sacituzumab tirumotecan IV on days 1, 15, and 29 of each 6-week cycle plus paclitaxel (arm 2). Primary outcomes for both substudies are safety and tolerability for the safety lead-in and ORR per RECIST v1.1. by BICR for the efficacy phase (calculated based on pooled data from safety lead-in and efficacy phase); secondary outcomes include DOR and PFS per RECIST v1.1 by BICR, OS, safety, and tolerability. Enrollment is ongoing in both substudies. Clinical trial information: NCT06469944 ; NCT06445972 .

Increasing RAS mutation result availability in newly diagnosed patients with metastatic colorectal cancer by their first outpatient medical oncology clinic visit at a large safety net hospital.

Journal of Clinical Oncology Viral M Patel, Anna Moscowitz, Robyn Cobb et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.110

110 Background: Rat sarcoma virus mutation testing (RASmt) is critical in guiding systemic therapy selection for patients with metastatic colorectal cancer (mCRC) in the first-line setting. Missing results at the initial medical oncology visit can negatively impact patient outcomes by delaying treatment or leading to inappropriate treatment selection. This quality improvement (QI) project aims to increase the percentage of patients with newly diagnosed mCRC with RASmt results available by their first outpatient medical oncology appointment at a large safety net hospital to 20% over an 8-month period. Methods: A multidisciplinary team of key stakeholders including clinicians, a pathologist, and administrators was assembled to determine factors associated with failure to obtain RASmt. A baseline analysis of all patients referred to the gastrointestinal (GI) oncology clinic from June 2022 to April 2023, with manual review of electronic medical records by investigators, showed that only 6% (3/46) of newly diagnosed patients with mCRC had RASmt results available by their first GI oncology appointment. Two Plan-Do-Study-Act (PDSA) cycles were conducted to assess interventions that were implemented based on process mapping and reasons for unavailable test results. To increase the percentage of patients with RASmt results available, starting December 2023, patients initially diagnosed with mCRC as inpatients who were being followed by the oncology consult service had RASmt ordered on the tissue biopsy prior to discharge (PDSA1). Starting April 2024, the medical directorfor outpatient GI oncology clinics ordered RASmt for all patients with mCRC referred to the clinic at the point of referral (PDSA2) . New patient referrals were reviewed through July 3, 2024. Results: At baseline, the most common reason for unavailable RASmt results was the lack of test orders, with 70% (32/46) of new patients with mCRC not having RASmt ordered prior to their first appointment. Once RASmt was ordered, the average time for results was 13 days. After the first intervention, 4% (1/23) of patients with mCRC had RASmt results available at their first appointment. After the second intervention, 42% (5/12) of patients had RASmt results available. Additionally, median time from diagnosis of mCRC to first appointment decreased from 23 days at baseline to 17 days during PDSA1 to 12 days during PDSA2. Conclusions: By ordering RASmt at the point of referral, the percentage of patients who had RASmt available at their first appointment markedly increased from 6% to 42%. This QI initiative additionally demonstrates the importance of multidisciplinary teams to enhance patient care efficiency at a large safety net hospital. Further efforts are ongoing to increase RASmt availability beyond 42% with a focus on reducing the turnaround time of the test.